Skip to content

GHRP-2 Stacking Guide: Best Combinations & Protocols (2026)

From Peptidepedia, the trusted peptide wiki.

Stacking

GHRP-2 + CJC-1295 (no DAC) / Mod GRF 1-29

This is the most widely used combination. The GHRH analog primes the pituitary somatotrophs while GHRP-2 amplifies the release signal through a separate receptor pathway, producing synergistic GH output that exceeds either agent alone by two to three times. See the peptide stacking guide for practical protocols combining these compounds. Typical dosing is 100 to 200 mcg of each peptide administered simultaneously in the same syringe, one to three times daily.

GHRP-2 + CJC-1295 (with DAC)

CJC-1295 with DAC has an extended half-life of approximately six to eight days, providing sustained baseline GHRH stimulation. Adding GHRP-2 injections on top of this creates acute GH pulses superimposed on a chronically elevated GHRH signal. This approach requires less frequent CJC-1295 dosing (once or twice weekly) but maintains daily GHRP-2 injections.

GHRP-2 + GHRH for Diagnostic Synergy

In clinical research settings, the combination of GHRP-2 with GHRH has been used as an enhanced provocative test for GH deficiency, leveraging the synergistic release to improve diagnostic sensitivity. The Mericq et al. (1998) pediatric study included a combined GHRP-2 + GHRH treatment arm that produced the highest GH responses observed.

When stacking, standard GHRP-2 dosing is maintained while the complementary peptide is added at its own standard dose. Timing rules (empty stomach, pre-bed priority) apply to both peptides.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Arvat E, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885-891.
  2. Mericq V, et al. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. Journal of Clinical Endocrinology & Metabolism. 1998;83(7):2355-2360.
  3. Berlanga-Acosta J, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clinical Medicine Insights: Cardiology. 2017;11:1179546817694558.
  4. Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37.
  5. Laferrere B, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. Journal of Clinical Endocrinology & Metabolism. 2005;90(2):611-614.
  6. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
  7. Pihoker C, et al. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature. Journal of Clinical Endocrinology & Metabolism. 1995;80(10):2987-2992.
  8. Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D. Drugs in R&D. 2004;5(4):236-239.
  9. Chihara K, et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol. 2007;157(1):19-27.
  10. Thomas A, et al. Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by LC-MS/MS. Rapid Communications in Mass Spectrometry. 2010;24(11):1549-1557.
  11. World Anti-Doping Agency. The 2026 Prohibited List International Standard.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”